decisionhealth Newsletters, Coder Pink Sheets - 2008 Issue 11 (November)
Use unclassified drug code to report Triesence – for now
Subscribe or sign in to view the full article.
Article Overview
This ophthalmology coding article discusses interim reporting for a newly approved intraocular drug, how payers and Medicare may handle claims before a specific HCPCS code is assigned, and the broader billing context in office and ambulatory surgical center settings. It also covers related procedure coding, documentation expectations, and general guidance on when additional reporting may or may not apply. The piece is aimed at coders, billers, and ophthalmology practices that need to understand current drug and injection billing requirements without relying on the eventual permanent code.
Why This Topic Matters
Prematurely using the wrong drug code or omitting required claim information can lead to denied claims or incorrect reimbursement. The article helps practices manage a temporary coding situation while staying aligned with payer and Medicare expectations.
Article Sections
-
Interim drug reporting and payer handling
Explains the temporary reporting situation for the drug and the need to coordinate claim submission with payer expectations. It also discusses how reimbursement is being handled before a permanent HCPCS assignment is available.
-
ASC payment context
Summarizes how the drug is handled under ambulatory surgical center payment policy and what documentation or billing support is needed in that setting.
-
Drug identification and related HCPCS distinctions
Addresses how the drug is identified in claims and compares it with other broadly related ophthalmic drug coding references. It emphasizes that the article is discussing coding distinctions rather than clinical treatment details.
-
The intraocular injection
Covers the associated procedure reporting for the eye injection and notes documentation expectations in the medical record.
-
Indications and bundled use during vitrectomy
Describes the general ophthalmic contexts in which the drug may be used and the relationship between drug reporting and a bundled surgical setting.
-
E/M billing
Reviews when an evaluation and management service may be considered alongside the injection encounter and the documentation considerations involved.
-
Coder's alert
Highlights a brief coding reminder related to the procedure designation discussed in the article.
What You Will Learn
- How a newly approved ophthalmic drug is handled before a permanent HCPCS code is issued
- What kinds of claim information may be needed for interim drug reporting
- How office and ASC settings affect drug billing
- How the related injection procedure is discussed in the article
- When evaluation and management reporting may be considered in the same encounter
- What documentation themes the article emphasizes for ophthalmology practices
Who Should Read This
- Ophthalmology coders
- Medical billers
- ASC billing staff
- Physician practices
- Revenue cycle staff
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com